揭示Zenocutuzumab的潜力：非小细胞肺癌和胰腺腺癌治疗的突破。

IF 1.8 4区医学 Q3 ONCOLOGY

Oncology-New York Pub Date : 2025-08-08 DOI:10.46883/2025.25921048

Sanan Rasheed Mbbs, Umer Farooq Mbbs, Aiman Waheed, Musharaf Khalid Bhutta Mbbs, Adnan Bhat Md, Hamza Nazir Mbbs, Muhammad Hamza Gul, Ayesha Aman Mbbs, Zainab Ibrahim Mbbs, Abdul Baseer Wardak

{"title":"揭示Zenocutuzumab的潜力：非小细胞肺癌和胰腺腺癌治疗的突破。","authors":"Sanan Rasheed Mbbs, Umer Farooq Mbbs, Aiman Waheed, Musharaf Khalid Bhutta Mbbs, Adnan Bhat Md, Hamza Nazir Mbbs, Muhammad Hamza Gul, Ayesha Aman Mbbs, Zainab Ibrahim Mbbs, Abdul Baseer Wardak","doi":"10.46883/2025.25921048","DOIUrl":null,"url":null,"abstract":"Zenocutuzumab-zbco, a novel bispecific antibody targeting HER2 and HER3, has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma. In early-phase clinical trials, it has shown an objective response rate of approximately 34% in HER2-amplified NSCLC and a disease control rate exceeding 70% in pancreatic adenocarcinoma with NRG1 fusions. By disrupting HER3-driven oncogenic signaling, zenocutuzumab effectively inhibits tumor proliferation and enhances therapeutic outcomes. Its safety profile remains favorable, with most adverse effects being mild to moderate. This editorial explores the clinical potential of zenocutuzumab in reshaping treatment strategies for NSCLC and pancreatic adenocarcinoma.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"null 7","pages":"298-300"},"PeriodicalIF":1.8000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment.\",\"authors\":\"Sanan Rasheed Mbbs, Umer Farooq Mbbs, Aiman Waheed, Musharaf Khalid Bhutta Mbbs, Adnan Bhat Md, Hamza Nazir Mbbs, Muhammad Hamza Gul, Ayesha Aman Mbbs, Zainab Ibrahim Mbbs, Abdul Baseer Wardak\",\"doi\":\"10.46883/2025.25921048\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Zenocutuzumab-zbco, a novel bispecific antibody targeting HER2 and HER3, has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma. In early-phase clinical trials, it has shown an objective response rate of approximately 34% in HER2-amplified NSCLC and a disease control rate exceeding 70% in pancreatic adenocarcinoma with NRG1 fusions. By disrupting HER3-driven oncogenic signaling, zenocutuzumab effectively inhibits tumor proliferation and enhances therapeutic outcomes. Its safety profile remains favorable, with most adverse effects being mild to moderate. This editorial explores the clinical potential of zenocutuzumab in reshaping treatment strategies for NSCLC and pancreatic adenocarcinoma.\",\"PeriodicalId\":51147,\"journal\":{\"name\":\"Oncology-New York\",\"volume\":\"null 7\",\"pages\":\"298-300\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology-New York\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.46883/2025.25921048\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology-New York","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46883/2025.25921048","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Zenocutuzumab-zbco是一种新的靶向HER2和HER3的双特异性抗体，在非小细胞肺癌（NSCLC）和胰腺腺癌中显示出良好的疗效。在早期临床试验中，它显示her2扩增的NSCLC的客观缓解率约为34%，NRG1融合的胰腺腺癌的疾病控制率超过70%。通过破坏her3驱动的致癌信号，zenocutuzumab有效抑制肿瘤增殖并提高治疗效果。其安全性仍然良好，大多数不良反应为轻度至中度。这篇社论探讨了zenocutuzumab在重塑非小细胞肺癌和胰腺腺癌治疗策略方面的临床潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment.

Zenocutuzumab-zbco, a novel bispecific antibody targeting HER2 and HER3, has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma. In early-phase clinical trials, it has shown an objective response rate of approximately 34% in HER2-amplified NSCLC and a disease control rate exceeding 70% in pancreatic adenocarcinoma with NRG1 fusions. By disrupting HER3-driven oncogenic signaling, zenocutuzumab effectively inhibits tumor proliferation and enhances therapeutic outcomes. Its safety profile remains favorable, with most adverse effects being mild to moderate. This editorial explores the clinical potential of zenocutuzumab in reshaping treatment strategies for NSCLC and pancreatic adenocarcinoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncology-New York 肿瘤学-肿瘤学

CiteScore

1.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.